The Technical Analyst
Zentalis Pharmaceuticals [ZNTL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Zentalis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.34% $12.54
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 889.84 mill |
| EPS: | -4.47 |
| P/E: | -2.81 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 70.96 mill |
| Avg Daily Volume: | 0.819 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.81 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.48x |
| Company: PE -2.81 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.271 (-102.16%) $-12.81 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 11.58 - 13.50 ( +/- 7.68%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Vultaggio Vincent | Sell | 0 | Common Stock |
| 2024-04-05 | Vultaggio Vincent | Sell | 12 500 | Stock Option (Right to Buy) |
| 2024-04-05 | Vultaggio Vincent | Sell | 10 000 | Stock Option (Right to Buy) |
| 2024-04-05 | Vultaggio Vincent | Sell | 6 875 | Stock Option (Right to Buy) |
| 2024-04-05 | Vultaggio Vincent | Sell | 2 750 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 85.17 |
| Last 97 transactions |
| Buy: 9 826 125 | Sell: 711 798 |
Forecast:
16:00 - $12.55
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $12.55
Forecast 2: 16:00 - $12.55
Forecast 3: 16:00 - $12.55
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $12.54 (-1.34% ) |
| Volume | 0.678 mill |
| Avg. Vol. | 0.819 mill |
| % of Avg. Vol | 82.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ZNTL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $11.59 | N/A | Active |
|---|
ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-04-02 16:05:00 - Press Release
Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity With Kras(g12c) Inhibitors At Aacr Annual Meeting 2024
Research supports azenosertib's potential to be highly synergistic in combination with kras targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents research supports azenosertib's potential to be highly synergistic in combination with kras targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents
2024-04-01 17:30:00 - Press Release
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New york and san diego, april 01, 2024 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on april 1, 2024, the compensation committee of zentalis' board of directors granted non-qualified stock options to purchase an aggregate of 105,950 shares of the company's common stock to four newly hired employees. the stock options were granted under the zentalis pharmaceuticals, inc. 2022 employment inducement incentive award plan (2022 inducement plan) as an inducement material to each such individual's entering into employment with zentalis in accordance with nasdaq listing rule 5635(c)(4).
2024-03-01 18:00:00 - Press Release
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New york & san diego, march 01, 2024 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on march 1, 2024, the compensation committee of zentalis' board of directors granted non-qualified stock options to purchase an aggregate of 125,000 shares of the company's common stock to two newly hired employees. the stock options were granted under the zentalis pharmaceuticals, inc. 2022 employment inducement incentive award plan (2022 inducement plan) as an inducement material to each such individual's entering into employment with zentalis in accordance with nasdaq listing rule 5635(c)(4).
2024-02-28 07:00:00 - Press Release
Zentalis Pharmaceuticals To Participate In Upcoming Investor Conferences
New york and san diego, feb. 28, 2024 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that zentalis management will participate in several upcoming investor conferences:
2024-02-27 07:00:00 - Press Release
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results And Operational Updates
Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer types during 2024
Latest News
2024-04-12 14:12:23 - Seeking Alpha
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%. Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024.
2024-02-28 10:56:07 - Zacks Investment Research
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-28 07:00:00 - GlobeNewsWire
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Zentalis management will participate in several upcoming investor conferences:
2024-02-08 13:01:05 - Zacks Investment Research
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Zentalis Pharmaceuticals, Inc. (ZNTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-02-07 02:32:48 - Seeking Alpha
Zentalis Pharmaceuticals: Azenosertib Continues To Impress
Zentalis Pharmaceuticals is positioned to become an oncology leader with its lead drug candidate, azenosertib, showing promising results in difficult-to-treat cancers. The company's financial health is strong, with a healthy cash reserve that will sustain operations until 2026. ZNTL is strategically expanding azenosertib's utility across wider indications and forming partnerships to reduce clinical trial risks and increase the likelihood of success.
2023-11-14 10:35:54 - Seeking Alpha
Zentalis: Latest Market Sell-Off Looks Justified With Data Catalysts Long Way Off
Zentalis is a biotech company focused on developing Azenosertib, a Wee1 inhibitor, for ovarian cancer. The company has faced stock sell-offs due to mixed data from clinical trials of Azenosertib in combination with chemotherapy, and as a monotherapy. Zentalis believes Azenosertib has potential and plans to submit a New Drug Application in 2026, but analysts have downgraded expectations.
2023-08-24 09:42:43 - Seeking Alpha
Zentalis: A Buy As Small Molecule Trials Continue To Advance
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's financials show a solid cash position and efficient allocation of resources. Zentalis has a diverse pipeline of oncological therapies in various stages of clinical trials, targeting different types of cancer.
2023-06-22 22:21:11 - 24/7 Wall Street
Matrix Capital Infuses $108 Million Into Zentalis Toward Promising Cancer Therapeutics
Shares of Zentalis Pharmaceuticals Inc (US:ZNTL) are cooling off a bit Thursday after yesterday's 4% rise capped a five-day rally of 17.8%.
2023-06-02 14:34:00 - The Motley Fool
Why Shares of Zentalis Pharmaceuticals Dropped This Week
Zentalis is a clinical-stage biotech that is focusing on cancer therapies. The stock is up more than 29% this year.
2023-04-26 10:00:00 - GlobeNewsWire
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib